A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment or mild Alzheimer’s disease dementia (ROMEMA): study protocol of a double-blind, randomized, placebo-controlled, between-subjects trial

Abstract Background Research into the neurobiological underpinnings of learning and memory has demonstrated the cognitive-enhancing effects associated with diverse classes of phosphodiesterase (PDE) inhibitors. Specific PDE inhibitors have been identified to improve neuronal communication through se...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Nina Possemis, Frans Verhey, Jos Prickaerts, Arjan Blokland, Inez Ramakers
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	BMC 2024-03-01
Цуврал:	Trials
Нөхцлүүд:	Mild cognitive impairment Dementia Alzheimer Cognitive dysfunction Roflumilast Phosphodiesterase 4
Онлайн хандалт:	https://doi.org/10.1186/s13063-024-08001-3
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!